Bruno Stephan

Mr. Bruno Stephan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Energy Research & Social Science
Verified
Journal Article
Closed access
Fabio SambataroFabio Sambataro
Fabio Sambataro
KWKyle Wilson
Kyle Wilson
SBSunhee Baik
Sunhee Baik
JCJuan Pablo Carvallo
Juan Pablo Carvallo
ADAnamika Dubey
Anamika Dubey
CHChristine A. Holland
Christine A. Holland

9 November 2023 in Journal of Global Health
Verified
Journal Article
Open access
Fabio SambataroFabio Sambataro
Fabio Sambataro
DGDantong Gu
Dantong Gu
BWBingjie Wang
Bingjie Wang
PKPauline Kang
Pauline Kang
KWKathleen Watt
Kathleen Watt
XZXingtao Zhou
Xingtao Zhou
Myopia is a refractive state where the ocular axial length is too long for its refractive power [1]. Its global prevalence was estimated to have increased from 28.3% to 34.0% between 2010 and 2020 [2], especially in East Asian countries including China [3]. According to a recent Chinese government official report, the overall prevalence of […]

23 June 2023 in Information Processing & Management
Verified
Journal Article
Closed access
YDYujuan Ding
Yujuan Ding
Fabio SambataroFabio Sambataro
Fabio Sambataro
YMYunshan Ma
Yunshan Ma
YBYi Bin
Yi Bin

26 September 2024 in Epidemics
Verified
Journal Article
Open access
Fabio SambataroFabio Sambataro
Fabio Sambataro
YWYunfan Wang
Yunfan Wang
GKGursharn Kaur
Gursharn Kaur
AAAniruddha Adiga
Aniruddha Adiga
BEBaltazar Espinoza
Baltazar Espinoza
MMMadhav Marathe
Madhav Marathe
The pandemic of COVID-19 has imposed tremendous pressure on public health systems and social economic ecosystems over the past years. To alleviate its social impact, it is important to proactively track the prevalence of COVID-19 within communities. The traditional way to estimate the disease prevalence is to estimate from reported clinical test data or surveys. However, the coverage of clinical tests is often limited and the tests can be labor-intensive, requires reliable and timely results, and consistent diagnostic and reporting criteria. Recent studies revealed that patients who are diagnosed with COVID-19 often undergo fecal shedding of SARS-CoV-2 virus into wastewater, which makes wastewater-based epidemiology for COVID-19 surveillance a promising approach to complement traditional clinical testing. In this paper, we survey the existing literature regarding wastewater-based epidemiology for COVID-19 surveillance and summarize the current advances in the area. Specifically, we have covered the key aspects of wastewater sampling, sample testing, and presented a comprehensive and organized summary of wastewater data analytical methods. Finally, we provide the open challenges on current wastewater-based COVID-19 surveillance studies, aiming to encourage new ideas to advance the development of effective wastewater-based surveillance systems for general infectious diseases.

22 October 2021 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
AMAlessandro Miola
Alessandro Miola
Michele FornaroMichele Fornaro
Michele Fornaro
Fabio SambataroFabio Sambataro
Fabio Sambataro
MSMarco Solm
Marco Solm

29 September 2021 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
AMAlessandro Miola
Alessandro Miola
VPVeronica Dal Porto
Veronica Dal Porto
NMNicola Meda
Nicola Meda
GPGiulia Perini
Giulia Perini
MSMarco Solmi
Marco Solmi
Fabio SambataroFabio Sambataro
Fabio Sambataro
A growing number of studies support a bidirectional relationship between inflammation and bipolar disorders. Tumor necrosis factor‐α (TNF‐α) inhibitors have recently attracted interest as potential therapeutic compounds for treating depressive symptoms, but the risk for triggering mood switches in patients with or without bipolar disorders remains controversial. Thus, we conducted a systematic review to study the anti‐TNF‐α medication‐induced manic or hypomanic episodes. PubMed, Scopus, Medline, and Embase databases were screened for a comprehensive literature search from inception until November 2020, using The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Out of the initial 75 references, the screening resulted in the inclusion of four case reports (each describing one patient) and a cohort study (in which 40 patients out of 7600–0.53% – experienced elated mood episodes after infliximab administration). Of these 44 patients, 97.7% experienced a manic episode and 2.3% hypomania. 93.2% of patients had no history of psychiatric disorder or psychotropic treatment. Only 6.8% had a history of psychiatric disorders with the affective spectrum (4.6% dysthymia and 2.3% bipolar disorder). The time of onset of manic or hypomanic symptoms varied across TNF‐α inhibitors with an early onset for Infliximab and a later onset for Adalimumab and Etanercept. These findings suggest that medications targeting the TNF‐α pathway may trigger a manic episode in patients with or without affective disorders. However, prospective studies are needed to evaluate the relative risk of such side effects and identify the population susceptible to secondary mania.